Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.17035 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Allyce Caines und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Alkaline Phosphatase, Autoantibodies, Liver Cirrhosis, Biliary, Racial Groups. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Intercept Pharmaceuticals.
Abstract (Originalsprache)
Background
Diagnosis of primary biliary cholangitis (PBC) is made using alkaline phosphatase (ALP) and positive antimitochondrial antibody (AMA), but these biomarkers may vary by race. There is also little known about changes in ALP in the years prior to PBC diagnosis.
Methods
Using data from the Fibrotic Liver Disease Consortium, we used matched pairs to evaluate racial differences in ALP for up to 5 years prior to diagnosis. We also compared rates of AMA positivity by race.
Results
1335 confirmed PBC patients were included: 769 (58%) non‐Hispanic white (NHW); 110 (8%) Black; 138 (11%) Asian American Pacific Islander (AAPI); and 318 (24%) Hispanic. 774 patients had AMA test results. Black patients had significantly lower AMA positivity than NHWs. Black patients were less likely to be AMA‐positive compared to NHW patients (OR = 0.50, 95% CI 0.29–0.86, p = 0.012). There were no significant differences in rates of AMA positivity between AAPI or Hispanic versus NHW patients. All patient groups had elevated ALP for 2–5 years prior to diagnosis. ALP differed between Black and NHW patients only at specific times before diagnosis. There were no significant differences in ALP between Hispanic and NHW patients. AAPI patients had significantly lower ALP compared to NHWs.
Conclusion
In a diverse sample of PBC patients, we observed significant differences in AMA positivity and pre‐diagnosis ALP levels by race. Future studies to better characterize PBC across racial/ethnic groups are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Michigan, USA.
- School of Medicine, Michigan State University, East Lansing, Michigan, USA.
- Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA.
- School of Medicine, Wayne State University, Detroit, Michigan, USA.
- Department of Research and Evaluation, Kaiser Permanente Southern California, Los Angeles, California, USA.
- Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
ORCID-Profile: Mei Lu, Stuart C Gordon
Förderung
- Intercept Pharmaceuticals
Zitieren
APA
Caines, A., Lu, M., Wu, T., Trudeau, S., Melkonian, C., Gonzalez, H. C., Sahota, A. K., Schmidt, M. A., Daida, Y., Bowlus, C. L., & Gordon, S. C. (2025). Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.17035
Vancouver
Caines A, Lu M, Wu T, Trudeau S, Melkonian C, Gonzalez HC, et al. Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.17035
BibTeX
@article{Caines2025,
author = {Caines, Allyce and Lu, Mei and Wu, Trueman and Trudeau, Sheri and Melkonian, Christina and Gonzalez, Humberto C and Sahota, Amandeep K and Schmidt, Mark A and Daida, Yihe and Bowlus, Christopher L and Gordon, Stuart C},
title = {Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.17035}
}
EUVIMED